reports
- ABGSC Capital Goods Research
- Anders Idborg
- Karl Bokvist
- Olof Cederholm
EQS-News: OHB SE: Konzernabschluss 2023
EQS-News: OHB SE / Schlagwort(e): Jahresergebnis OHB SE: Konzernabschluss 2023 23.04.2024 / 08:00 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. OHB SE: Konzernabschluss 2023 Gesamtleistung erreicht EUR 1.183 Mio. Dividendenvorschlag beträgt EUR 0,60 Freiwilliges öffentliches Übernahmeangebot schreitet planmäßig voran Der OHB-Konzern (ISIN: DE0005936124, Prime Standard) erreichte im Geschäftsjahr 2023 eine Gesamtleistung von EUR 1.182,8 Mio. (Vorjahr: EUR 1.001,3 Mio.), der Umsatz veränderte sich auf EUR 1.047,8 Mio. (Vorjahr: EUR...
Cairn Homes Plc: Transaction in Own Shares
Cairn Homes Plc (CRN) Cairn Homes Plc: Transaction in Own Shares 23-Apr-2024 / 07:00 GMT/BST 23 April 2024 Cairn Homes plc (the “Company”) Transaction in own shares The Company announces that on 22nd of April 2024 it purchased a total of 95,711 of its ordinary shares of EUR 0.001 each (the "ordinary shares") on Euronext Dublin and the London Stock Exchange through the Company's broker Goodbody Stockbrokers UC (“Goodbody”), as detailed below. The repurchased shares will be cancelled. Euronext Dublin London Stock Exchange Number o...
EQS-News: OHB SE: Consolidated financial statements 2023
EQS-News: OHB SE / Key word(s): Annual Results OHB SE: Consolidated financial statements 2023 23.04.2024 / 08:00 CET/CEST The issuer is solely responsible for the content of this announcement. OHB SE: Consolidated financial statements 2023 Total revenues reach EUR 1,183 million Dividend recommendation amounts to EUR 0.60 Voluntary public takeover offer progressing according to plan In fiscal year 2023, the OHB Group (ISIN: DE0005936124, Prime Standard) generated total revenues of EUR 1,182.8 (previous year: EUR 1,001.3 million), while sales changed to EUR 1,047.8 milli...
Full year trading update and notice of results
Molten Ventures Plc (GROW; GRW) Full year trading update and notice of results 23-Apr-2024 / 07:00 GMT/BST 23 April 2024 Molten Ventures plc ("Molten Ventures", "Molten", or the “Group”) Full year trading update and notice of results Stable and enhanced platform, in an improving market with greater expectation for realisations Molten Ventures (LSE: GROW, Euronext Dublin: GRW), a leading venture capital firm investing in and developing high-growth digital technology businesses, today announces an update on its portfolio, NAV (unaudited) and highlights for the year ...
EQS-News: DEFENCE’S ACCUTOX ANTI-CANCER ARM-002 VACCINE EXHIBITS POTEN...
EQS-News: Defence Therapeutics Inc. / Key word(s): Miscellaneous DEFENCE’S ACCUTOX ANTI-CANCER ARM-002 VACCINE EXHIBITS POTENT ANTIGEN PRESENTATION 23.04.2024 / 08:00 CET/CEST The issuer is solely responsible for the content of this announcement. Vancouver, BC, Canada, April 23rd, 2024 - Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a Canadian biopharmaceutical company developing novel immune-oncology therapeutics and drug delivery technologies, is pleased to announce that its second-generation ARMTM anti-cancer vaccine using ...
EQS-News: Screening completed: Berlin Cures achieves key milestone in ...
Issuer: Berlin Cures Holding AG / Key word(s): Miscellaneous Screening completed: Berlin Cures achieves key milestone in BC 007 Phase II Trial for treatment of Long COVID 23.04.2024 / 08:00 CET/CEST The issuer is solely responsible for the content of this announcement. Berlin, Germany, 23 April 2024 – Berlin Cures, a pioneering clinical-stage biotechnology company, today announced the successful completion of patient screening for its pan-European Phase II trial of BC 007 (Rovunaptabin), a novel therapeutic candidate for the treatment of Long COVID. The study has now recr...
EQS-News: ekrutierung abgeschlossen: Berlin Cures erreicht wichtigen M...
Emittent / Herausgeber: Berlin Cures Holding AG / Schlagwort(e): Sonstiges ekrutierung abgeschlossen: Berlin Cures erreicht wichtigen Meilenstein in der Phase-II-Studie mit BC 007 zur Behandlung von Long COVID 23.04.2024 / 08:00 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Berlin, 23. April 2024 – Berlin Cures, ein Biotechnologieunternehmen in der klinischen Phase, hat heute den erfolgreichen Abschluss der Patientenrekrutierung für seine europaweite Phase-II-Studie mit BC 007 (Rovunaptabin) bekanntgegeben. BC 007 ist Berlin Cures‘ ...
United Airlines Holdings Inc: 1 director
A director at United Airlines Holdings Inc sold 30,000 shares at 50.843USD and the significance rating of the trade was 74/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ...
- Oliver Metzger
- Stephan Wulf
Dermapharm Holding SE : Smooth integration of Arkopharma and declining...
>2023 net earnings also burdened by accounting-related charges - While the final sales and EBITDA figures confirmed the preliminary results released on 14 March, the net result for 2023 published for the first time obviously led to disappointment in the market. The significant increase in financial expenses (c +400% to € 73m), together with the lower operating result (-25%) due to the absence of the vaccine business, led to a significantly lower net result of € 60.5m ...
- Baptiste Lebacq
Saipem : Q1 2024 slightly lower than expectations
>EBIT 2% below expectations - Q1 2024 sales came in 18% higher y-o-y at € 3.05bn (in line with the FactSet consensus at € 3.06bn). EBITDA came to € 268m, or a margin of 8.8% (below consensus of € 272m), driven by offshore businesses (€ 180m from asset-based services, € 80m for offshore drilling and € 8m for energy carriers). The energy carriers division continues to be undermined by challenging contracts. All told, this division’s EBITDA margin came to 0.7%, an...
- ABGSC Construct. & Real Estate Research
- Bengt Jonassen
- Njål Kleiven
- ABGSC Construct. & Real Estate Research
- Fredrik Stensved
- Markus Henriksson
- Viktor Stenlöf
Arco Vara AS will hold an investor webinar to introduce the results fo...
Arco Vara AS will hold an investor webinar to introduce the results for the Q1 2024 Arco Vara invites all interested parties to join its investor webinar, scheduled on 25 April 2024 at 10 am (EET). The webinar will be held in Estonian. The webinar will be hosted by the CEO of Arco Vara Miko-Ove Niinemäe, who presents the unaudited financial results of the Q1 2024. The webinar takes place at the link: The webinar will be recorded and remains public on the company's website. Tiina Malm CFO Arco Vara AS
KBC Group: Update regarding the KBC Group share buyback programme
KBC Group: Update regarding the KBC Group share buyback programme Within the framework of the share buyback programme announced on 10 August 2023 after trading hours, KBC Group NV wishes to advise that the following transactions took place on Euronext Brussels’ regulated market between 15 April 2024 and 19 April 2024, included: Date No. of shares Total price Average price Lowest price Highest price 15-04-2024 72 000 € 4 947 120 € 68.71 € 68.40 € 69.24 16-04-2024 75 000 € 5 071 792 € 67.62 € 67.28 € 68.00 17-04-2024 72 000 € 4 941 259 € 68.63 € 67.90 € 69.24 18-04...
KBC Groupe: Mise à jour concernant le programme de rachat d’actions pr...
KBC Groupe: Mise à jour concernant le programme de rachat d’actions propres de KBC Groupe Dans le cadre du programme de rachat d'actions propres, annoncé le 10 août 2023 hors séance boursière, KBC Groupe SA souhaite communiquer que les transactions suivantes ont eu lieu sur le marché réglementé de Euronext Bruxelles entre 15 avril 2024 et 19 avril 2024 inclus: DateNo. des actionsPrix totalPrix moyenPrix plus basPrix plus haut15-04-202472 000€ 4 947 120€ 68.71€ 68.40€ 69.2416-04-202475 000€ 5 071 792€ 67.62€ 67.28€ 68.0017-04-202472 000€ 4 941 259€ 68.63€ 67.90€ 69.2418-04-202470 000€ 4 883 ...
KBC Groep: Update m.b.t. inkoopprogramma van KBC Groep voor eigen aand...
KBC Groep: Update m.b.t. inkoopprogramma van KBC Groep voor eigen aandelen In het kader van het inkoopprogramma voor eigen aandelen dat werd aangekondigd op 10 augustus 2023 na beurstijd, wenst KBC Groep te melden dat de volgende transacties plaatsvonden op de gereglementeerde markt van Euronext Brussel van 15 april 2024 tot en met 19 april 2024: DatumAantal aandelenTotaalprijsGemiddelde prijsLaagste prijsHoogste prijs15-04-202472 000€ 4 947 120€ 68.71€ 68.40€ 69.2416-04-202475 000€ 5 071 792€ 67.62€ 67.28€ 68.0017-04-202472 000€ 4 941 259€ 68.63€ 67.90€ 69.2418-04-202470 000€ 4 883 179€ 69...
Legrand poursuit ses investissements dans les segments porteurs
LIMOGES, France--(BUSINESS WIRE)-- Regulatory News: Legrand (Paris:LR) poursuit activement sa stratégie de développement avec l’annonce de deux acquisitions dans les domaines porteurs de l’assistance à l’autonomie et la santé ainsi que dans les datacenters, venant renforcer les positions de leadership du Groupe dans ses segments à plus forte croissance. Enovation est le leader néerlandais des logiciels de santé dans le marché de la santé connectée et de l’assistance à l’autonomie. Spécialisées en B to B, les solutions d’Enovation intègrent notamment des offres logicielles pour la télésur...
Arco Vara AS korraldab 2024. aasta I kvartali majandustulemuste tutvus...
Arco Vara AS korraldab 2024. aasta I kvartali majandustulemuste tutvustamiseks veebiseminari Arco Vara kutsub kõiki huvilisi osalema veebiseminaril 25. aprillil 2024 kell 10.00. Veebiseminar toimub eesti keeles. Seminaril tutvustab 2024. aasta I kvartali auditeerimata majandustulemusi grupi tegevjuht Miko-Ove Niinemäe. Ülekanne toimub lingil: Veebiseminar salvestatakse ning jääb avalikuks ettevõtte kodulehel. Tiina MalmFinantsjuht Arco Vara AS
Transaction in Own Shares
Transaction in Own Shares ICG Enterprise Trust plc (the “Company”) 23 April 2024 Transaction in Own Shares The Company announces that on 22 April 2024 it bought back 10,000 of its own shares, to be held as treasury shares, at an average price of 1206 pence per share. Further details are set out below: Number of shares held as treasury shares following this purchase: 6,293,133.Total shares in issue excluding treasury shares following this purchase: 66,619,867. The Company has bought back these shares under the authority granted by shareholders at its Annual General Meeting in June 2023...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.